Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Strabag, Valneva, Semperit (13/11/2019)

17.11.2019

Strabag: The publicly listed European-based construction group Strabag announced its figures for the first nine months of 2019 along with an outlook on the 2019 full year with an updated output volume. The company generated revenue of Euro 12,150.23 mn in the first nine months of the 2019 financial year. This upward movement of 4 % reflects the high demand in all of the group’s core markets with the exception of Slovakia. The order backlog as at 30 September 2019 weakened slightly on the year, falling by 2 % to Euro 17,733.68 mn, but clearly exceeded the value of one year’s output volume and so remained at a very high level. For the current 2019 financial year, STRABAG now expects to generate an output volume at least as high as the record of the previous year of Euro 16.3 bn. The previous assessment only expected to exceed the Euro 16.0 bn mark. The forecast for an EBIT margin of at least 3.3 % remains in place, as does the outlook for net investments (cash flow from investing activities), which should reach a maximum of Euro 550 mn in 2019.
Strabag: weekly performance: 1.64%

Valneva: Valneva SE, a French/Austrian biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, today announced the appointment of two leading vaccine experts to its Scientific Advisory Board (SAB). Norman W. Baylor and George R. Siber, will join Valneva’s SAB starting December 1, 2019.
Valneva: weekly performance: -1.95%

Semperit: Based on the current insights of the Executive Board of rubber products developer Semperit AG Holding into the competitive environment of the medical business, a significant impairment loss might occur in the Medical Sector (Sempermed segment). The publication of the interim Group report as of 30 September 2019, which was planned for 21 November 2019, will be postponed; the new date will be announced separately. On 21 November 2019, a shortened reporting will be presented.
Semperit: weekly performance: -7.53%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (13/11/2019)


Partners









latest 21st Austria

21st Austria weekly - Strabag, Valneva, Semperit (13/11/2019)


17.11.2019


Strabag: The publicly listed European-based construction group Strabag announced its figures for the first nine months of 2019 along with an outlook on the 2019 full year with an updated output volume. The company generated revenue of Euro 12,150.23 mn in the first nine months of the 2019 financial year. This upward movement of 4 % reflects the high demand in all of the group’s core markets with the exception of Slovakia. The order backlog as at 30 September 2019 weakened slightly on the year, falling by 2 % to Euro 17,733.68 mn, but clearly exceeded the value of one year’s output volume and so remained at a very high level. For the current 2019 financial year, STRABAG now expects to generate an output volume at least as high as the record of the previous year of Euro 16.3 bn. The previous assessment only expected to exceed the Euro 16.0 bn mark. The forecast for an EBIT margin of at least 3.3 % remains in place, as does the outlook for net investments (cash flow from investing activities), which should reach a maximum of Euro 550 mn in 2019.
Strabag: weekly performance: 1.64%

Valneva: Valneva SE, a French/Austrian biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, today announced the appointment of two leading vaccine experts to its Scientific Advisory Board (SAB). Norman W. Baylor and George R. Siber, will join Valneva’s SAB starting December 1, 2019.
Valneva: weekly performance: -1.95%

Semperit: Based on the current insights of the Executive Board of rubber products developer Semperit AG Holding into the competitive environment of the medical business, a significant impairment loss might occur in the Medical Sector (Sempermed segment). The publication of the interim Group report as of 30 September 2019, which was planned for 21 November 2019, will be postponed; the new date will be announced separately. On 21 November 2019, a shortened reporting will be presented.
Semperit: weekly performance: -7.53%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (13/11/2019)




 

Bildnachweis

Aktien auf dem Radar: Warimpex , Zumtobel , Bawag , Addiko Bank , Marinomed Biotech , FACC , Verbund , Agrana , Österreichische Post , Rosenbauer , AMS , Vonovia SE , Wirecard , Adler Real Estate , Hochtief , Manz , Stratec Biomedical , Deutsche Bank , Andritz .


Random Partner

Baader Bank
Die Baader Bank ist eine der führenden familiengeführten Investmentbanken im deutschsprachigen Raum. Die beiden Säulen des Baader Bank Geschäftsmodells sind Market Making und Investment Banking. Als Spezialist an den Börsenplätzen Deutschland, Österreich und der Schweiz handelt die Baader Bank über 800.000 Finanzinstrumente.

>> Besuchen Sie 52 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten